Research team for Abiomed's battery heart expands
This article was originally published in Clinica
Abiomed is preparing for clinical trials of its battery-powered heart after finalising several collaborative agreements with five US medical centres, as part of its drive to expand its project and research team. The company is building a fully-implantable heart as a permanent replacement for a diseased organ.
You may also be interested in...
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.
Netherlands' Authority for Consumers and Markets has reprimanded a dietary supplements player for purchasing fake followers and likes on social media to exaggerate the popularity of its products. It is the first case of its kind in the country.